This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowReprints and Permissions
Right arrow Copyright Information
Right arrow Books from ASM Press
Right arrow MicrobeWorld
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Ason, B.
Right arrow Articles by Reznikoff, W. S.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Ason, B.
Right arrow Articles by Reznikoff, W. S.

 Previous Article  |  Next Article 

Antimicrobial Agents and Chemotherapy, May 2005, p. 2035-2043, Vol. 49, No. 5
0066-4804/05/$08.00+0     doi:10.1128/AAC.49.5.2035-2043.2005
Copyright © 2005, American Society for Microbiology. All Rights Reserved.

Targeting Tn5 Transposase Identifies Human Immunodeficiency Virus Type 1 Inhibitors

Brandon Ason,1,{dagger} Daniel J. Knauss,2 Allison M. Balke,1 George Merkel,3 Anna Marie Skalka,3 and William S. Reznikoff1*

Department of Biochemistry, University of Wisconsin—Madison, 433 Babcock Drive, Madison, Wisconsin 53706-1544,1 McArdle Laboratory for Cancer Research, Department of Oncology, University of Wisconsin—Madison, 1400 University Avenue, Madison, Wisconsin 53706-1599,2 Fox Chase Cancer Center, Institute for Cancer Research, 333 Cottman Avenue, Philadelphia, Pennsylvania 19111-24973

Received 9 August 2004/ Returned for modification 12 October 2004/ Accepted 29 December 2004

Human immunodeficiency virus (HIV) type 1 (HIV-1) integrase is an underutilized drug target for the treatment of HIV infection. One limiting factor is the lack of costructural data for use in the rational design or modification of integrase inhibitors. Tn5 transposase is a structurally well characterized, related protein that may serve as a useful surrogate. However, little data exist on inhibitor cross-reactivity. Here we screened 16,000 compounds using Tn5 transposase as the target and identified 20 compounds that appear to specifically inhibit complex assembly. Six were found to also inhibit HIV-1 integrase. These compounds likely interact with a highly conserved region presumably within the catalytic core. Most promising, several cinnamoyl derivatives were found to inhibit HIV transduction in cells. The identification of integrase inhibitors from a screen using Tn5 transposase as the target illustrates the utility of Tn5 as a surrogate for HIV-1 integration even though the relationship between the two systems is limited to the active site architecture and catalytic mechanism.

* Corresponding author. Mailing address: Department of Biochemistry, University of Wisconsin—Madison, 433 Babcock Drive, Madison, WI 53706-1544. Phone: (608) 262-3608. Fax: (608) 265-2603. E-mail: reznikoff{at}biochem.wisc.edu.

{dagger} Present address: Hubrecht Laboratory, Uppsalalaan 8, 3584 CT, Utrecht, The Netherlands.

Antimicrobial Agents and Chemotherapy, May 2005, p. 2035-2043, Vol. 49, No. 5
0066-4804/05/$08.00+0     doi:10.1128/AAC.49.5.2035-2043.2005
Copyright © 2005, American Society for Microbiology. All Rights Reserved.





Copyright © 2009 by the American Society for Microbiology.   For an alternate route to Journals.ASM.org, visit: http://intl-journals.asm.org | More Info»